Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey
Authors
Keywords
-
Journal
Diabetes & Vascular Disease Research
Volume 17, Issue 4, Pages 147916412094567
Publisher
SAGE Publications
Online
2020-07-29
DOI
10.1177/1479164120945674
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care
- (2019) Elisabetta Patorno et al. CIRCULATION
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus
- (2018) Michael d'Emden et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
- (2018) Sandeep R. Das et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project
- (2017) Suzanne V Arnold et al. European Journal of Preventive Cardiology
- Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
- (2017) Andrew McGovern et al. Diabetes Therapy
- Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
- (2017) Andrew McGovern et al. Diabetes Therapy
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preventable Coronary Heart Disease Events from Control of Cardiovascular Risk Factors in US Adults With Diabetes (Projections from Utilizing the UKPDS Risk Engine)
- (2014) Nathan D. Wong et al. AMERICAN JOURNAL OF CARDIOLOGY
- Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: Comparison by prevalent cardiovascular disease status
- (2013) Nathan D Wong et al. Diabetes & Vascular Disease Research
- External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?
- (2012) C. Saunders et al. DIABETIC MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now